Literature DB >> 17308895

Incidence and risk factors for newly acquired hepatitis C virus infection among Aboriginal versus non-Aboriginal Canadians in six regions, 1999-2004.

H-X Wu1, J Wu, T Wong, A Andonov, Q Li, K Dinner, T Donaldson, S Paton.   

Abstract

The purpose of this study was to compare hepatitis C virus (HCV) incidence and recent patterns of transmission within Aboriginal and non-Aboriginal Canadians. Cases of newly acquired HCV infection (in patients > or =15 years) reported to the Enhanced Hepatitis Strain Surveillance System from six jurisdictions in Canada were analyzed. Information on demographic and clinical characteristics as well as risk factors for HCV infection was collected using standardized questionnaires. Univariate analysis showed Aboriginal patients to be significantly more likely than non-Aboriginal patients to report injection drug use (77.1% vs. 64.0%; p < 0.05), to be female (54.6% vs. 37.6%; p < 0.05), to report high-risk sexual behaviors (48.6% vs. 34.1%, p < 0.05), and to report drug snorting (45.7% vs. 32.7%, p < 0.05). The median age of Aboriginal patients was significantly younger than that of non-Aboriginal patients (31 years [range, 15-71] vs. 34 years [range, 15-81]; p < 0.05). The overall incidence of HCV infection per 100,000 people aged 15 years and older was 18.9 (95% confidence interval [CI] 15.5-23.1) in Aboriginal people and 2.8 (95%CI 2.6-3.1) in non-Aboriginal people. Poisson regression analysis revealed that Aboriginal Canadians were more likely than non-Aboriginal Canadians to develop acute hepatitis C (adjusted rate ratio 5.8, 95%CI 4.7-7.3). An appropriate and effective public health strategy that includes planned and implemented prevention programs in partnership with the Aboriginal community is needed.

Entities:  

Mesh:

Year:  2007        PMID: 17308895     DOI: 10.1007/s10096-007-0267-7

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  20 in total

Review 1.  Viral hepatitis in the Canadian Inuit and First Nations populations.

Authors:  Gerald Y Minuk; J Uhanova
Journal:  Can J Gastroenterol       Date:  2003-12       Impact factor: 3.522

Review 2.  Hepatitis C: who is at risk and how do we identify them?

Authors:  D Goldberg; E Anderson
Journal:  J Viral Hepat       Date:  2004-09       Impact factor: 3.728

Review 3.  The embodiment of inequity: health disparities in aboriginal Canada.

Authors:  Naomi Adelson
Journal:  Can J Public Health       Date:  2005 Mar-Apr

Review 4.  Hepatitis C virus infection in the United States.

Authors:  M J Alter
Journal:  J Hepatol       Date:  1999       Impact factor: 25.083

5.  Race, socioeconomic status, and cause-specific mortality.

Authors:  G Howard; R T Anderson; G Russell; V J Howard; G L Burke
Journal:  Ann Epidemiol       Date:  2000-05       Impact factor: 3.797

6.  Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection.

Authors:  D M Patrick; M W Tyndall; P G Cornelisse; K Li; C H Sherlock; M L Rekart; S A Strathdee; S L Currie; M T Schechter; M V O'Shaughnessy
Journal:  CMAJ       Date:  2001-10-02       Impact factor: 8.262

7.  Sharing of drug preparation equipment as a risk factor for hepatitis C.

Authors:  H Hagan; H Thiede; N S Weiss; S G Hopkins; J S Duchin; E R Alexander
Journal:  Am J Public Health       Date:  2001-01       Impact factor: 9.308

8.  Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study.

Authors:  Johannes Wiegand; Peter Buggisch; Wulf Boecher; Stefan Zeuzem; Cornelia M Gelbmann; Thomas Berg; Wolfgang Kauffmann; Birgit Kallinowski; Markus Cornberg; Elmar Jaeckel; Heiner Wedemeyer; Michael P Manns
Journal:  Hepatology       Date:  2006-02       Impact factor: 17.425

9.  Enhanced surveillance of acute hepatitis B and C in four health regions in Canada, 1998 to 1999.

Authors:  S Zou; J Zhang; M Tepper; A Giulivi; B Baptiste; G Predy; D Poliquin; M Morin; D Jones; J Lowewen; M Ogonowski; S Moses; L Elliott
Journal:  Can J Infect Dis       Date:  2001-11

10.  Risk factors for elevated HIV incidence among Aboriginal injection drug users in Vancouver.

Authors:  Kevin J P Craib; Patricia M Spittal; Evan Wood; Nancy Laliberte; Robert S Hogg; Kathy Li; Katherine Heath; Mark W Tyndall; Michael V O'Shaughnessy; Martin T Schechter
Journal:  CMAJ       Date:  2003-01-07       Impact factor: 8.262

View more
  12 in total

1.  Building on the Resilience of Aboriginal People in Risk Reduction Initiatives Targeting Sexually Transmitted Infections and Blood-Borne Viruses: The Aboriginal Community Resilience to AIDS (ACRA).

Authors:  Neil Andersson; Bev Shea; Chris Archibald; Tom Wong; Kevin Barlow; Georges Sioui
Journal:  Pimatisiwin       Date:  2008

2.  The potential influence of KIR cluster profiles on disease patterns of Canadian Aboriginals and other indigenous peoples of the Americas.

Authors:  Julia D Rempel; Kim Hawkins; Erin Lande; Peter Nickerson
Journal:  Eur J Hum Genet       Date:  2011-07-06       Impact factor: 4.246

3.  Hepatitis C infection among pregnant women in British Columbia: reported prevalence and critical appraisal of current prenatal screening methods.

Authors:  Audrey Blasig; Emily C Wagner; David Pi; Mark Bigham; Valencia P Remple; Kevin J P Craib; Patrick Doyle; Simon Dobson; Eric M Yoshida; David Patrick; Mel Krajden; Deborah M Money
Journal:  Can J Public Health       Date:  2011 Mar-Apr

4.  First Nations hepatitis C virus infections: Six-year retrospective study of on-reserve rates of newly reported infections in northwestern Ontario.

Authors:  Janet Gordon; Natalie Bocking; Kathy Pouteau; Terri Farrell; Gareth Ryan; Len Kelly
Journal:  Can Fam Physician       Date:  2017-11       Impact factor: 3.275

5.  Culturally Competent Service Provision Issues Experienced By Aboriginal People Living With HIV/AIDS.

Authors:  Kevin Barlow; Charlotte Loppie; Randy Jackson; Margaret Akan; Lynne Maclean; Gwen Reimer
Journal:  Pimatisiwin       Date:  2008

6.  A collaborative approach to hepatitis C testing in two First Nations communities of northwest Ontario.

Authors:  David Smookler; Anne Beck; Brenda Head; Leroy Quoquat; Cheyanne Albany; Terri Farrell; Janet Gordon; Nancy Thurston; Lucy You; Camelia Capraru; Mike McKay; John Kim; Jordan J Feld; Hemant Shah
Journal:  Can Liver J       Date:  2022-08-16

7.  Outcomes of peginterferon alpha-2a and ribavirin hepatitis C therapy in Aboriginal Canadians.

Authors:  Curtis L Cooper; Robert J Bailey; Vince G Bain; Frank Anderson; Eric M Yoshida; Mel Krajden; Paul Marotta
Journal:  Can J Gastroenterol       Date:  2008-08       Impact factor: 3.522

8.  Favourable IFNL3 genotypes are associated with spontaneous clearance and are differentially distributed in Aboriginals in Canadian HIV-hepatitis C co-infected individuals.

Authors:  Nasheed Moqueet; Claire Infante-Rivard; Robert W Platt; Jim Young; Curtis Cooper; Mark Hull; Sharon Walmsley; Marina B Klein
Journal:  Int J Mol Sci       Date:  2015-03-20       Impact factor: 5.923

Review 9.  Hepatitis C virus in American Indian/Alaskan Native and Aboriginal peoples of North America.

Authors:  Julia D Rempel; Julia Uhanova
Journal:  Viruses       Date:  2012-12       Impact factor: 5.048

10.  Distribution of Hepatitis C Risk Factors and HCV Treatment Outcomes among Central Canadian Aboriginal.

Authors:  Parmvir Parmar; Daniel J Corsi; Curtis Cooper
Journal:  Can J Gastroenterol Hepatol       Date:  2016-04-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.